386 related articles for article (PubMed ID: 33849094)
21. T lymphocyte subsets and PD-1 expression on lymphocytes in peripheral blood of patients with non-small cell lung cancer.
Chen T; Chen H; Lu W; Yao Y
Medicine (Baltimore); 2022 Oct; 101(42):e31307. PubMed ID: 36281084
[TBL] [Abstract][Full Text] [Related]
22. Changes in T lymphocyte subsets in peripheral blood of patients with middle-advanced cervical cancer before and after nimotuzumab combined with concurrent chemoradiotherapy.
Ao M; Li P; Sun D; Li X; Xu S; Hao Y
J Obstet Gynaecol; 2023 Dec; 43(1):2179915. PubMed ID: 37001548
[TBL] [Abstract][Full Text] [Related]
23. Exploring the relationship between intestinal microbiota and immune checkpoint inhibitors in the treatment of non-small cell lung cancer: insights from the "lung and large intestine stand in exterior-interior relationship" theory.
Li L; Zhong H; Wang Y; Pan Z; Xu S; Li S; Zeng G; Zhang W; Li J; He L
Front Cell Infect Microbiol; 2024; 14():1341032. PubMed ID: 38415012
[TBL] [Abstract][Full Text] [Related]
24. High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study.
Sumiyoshi I; Okabe T; Togo S; Takagi H; Motomura H; Ochi Y; Shimada N; Haraguchi M; Shibayama R; Fujimoto Y; Watanabe J; Iwai M; Kadoya K; Iwakami SI; Takahashi K
J Transl Med; 2021 Feb; 19(1):92. PubMed ID: 33639962
[TBL] [Abstract][Full Text] [Related]
25. A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers.
Ayers KL; Ma M; Debussche G; Corrigan D; McCafferty J; Lee K; Newman S; Zhou X; Hirsch FR; Mack PC; Liu JJ; Schadt EE; Chen R; Li SD
BMC Cancer; 2021 Apr; 21(1):441. PubMed ID: 33882890
[TBL] [Abstract][Full Text] [Related]
26. Impact of endogenous glucocorticoid on response to immune checkpoint blockade in patients with advanced cancer.
Cui Y; Han X; Liu H; Xie Q; Guan Y; Yin B; Xiao J; Feng D; Wang X; Li J; Chen J; Liu X; Li X; Nie W; Ma L; Liu H; Liang J; Li Y; Wang B; Wang J
Front Immunol; 2023; 14():1081790. PubMed ID: 37114049
[TBL] [Abstract][Full Text] [Related]
27. Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs).
Li Y; Zhang Z; Hu Y; Yan X; Song Q; Wang G; Chen R; Jiao S; Wang J
Front Oncol; 2020; 10():654. PubMed ID: 32656072
[No Abstract] [Full Text] [Related]
28. New biomarkers exploration and nomogram construction of prognostic and immune-related adverse events of advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors.
Lin X; Chen X; Long X; Zeng C; Zhang Z; Fang W; Xu P
Respir Res; 2023 Feb; 24(1):64. PubMed ID: 36849947
[TBL] [Abstract][Full Text] [Related]
29. Inflammation-nutritional markers of peripheral blood could predict survival in advanced non-small-cell lung cancer patients treated with PD-1 inhibitors.
Pu D; Xu Q; Zhou LY; Zhou YW; Liu JY; Ma XL
Thorac Cancer; 2021 Nov; 12(21):2914-2923. PubMed ID: 34581010
[TBL] [Abstract][Full Text] [Related]
30. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors.
Peng L; Wang Y; Liu F; Qiu X; Zhang X; Fang C; Qian X; Li Y
Cancer Immunol Immunother; 2020 Sep; 69(9):1813-1822. PubMed ID: 32350592
[TBL] [Abstract][Full Text] [Related]
31. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
32. Changes in T lymphocyte subsets predict the efficacy of atezolizumab in advanced non-small cell lung cancer: a retrospective study.
Wang Y; Zhu J; Zhou N; Wang Y; Zhang X
J Thorac Dis; 2023 Oct; 15(10):5669-5679. PubMed ID: 37969284
[TBL] [Abstract][Full Text] [Related]
33. Immunomodulatory effects of chemotherapy on blood lymphocytes and survival of patients with advanced non-small cell lung cancer.
Aldarouish M; Su X; Qiao J; Gao C; Chen Y; Dai A; Zhang T; Shu Y; Wang C
Int J Immunopathol Pharmacol; 2019; 33():2058738419839592. PubMed ID: 30968711
[TBL] [Abstract][Full Text] [Related]
34. [Therapeutic efficacy analysis of immunotherapy in small cell lung cancer].
Zhong J; Zheng QW; Zhao J; Wang ZP; Wu MN; Zhuo ML; Wang YY; Li JJ; Yang X; Chen HX; An TT
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):771-776. PubMed ID: 32988161
[No Abstract] [Full Text] [Related]
35. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
[TBL] [Abstract][Full Text] [Related]
36. [Peripheral Blood Laboratory Test Results Combined with TCF1+CD8+ T Lymphocytes
Ratio to Predict the Response and Prognosis of Immunotherapy to
Advanced Lung Cancer].
Luo H; Dai S; Li Y; Tian P; Li Q; Cai X
Zhongguo Fei Ai Za Zhi; 2023 Aug; 26(8):605-614. PubMed ID: 37752540
[TBL] [Abstract][Full Text] [Related]
37. [Expression of PD-1 and PD-L1 in the peripheral blood of advanced non-small-cell lung cancer patients and its implications].
Xing YF; Pan X; Qian B; Shi MH
Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(2):111-114. PubMed ID: 30669748
[No Abstract] [Full Text] [Related]
38. PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors.
Meniawy TM; Lake RA; McDonnell AM; Millward MJ; Nowak AK
Lung Cancer; 2016 Mar; 93():9-16. PubMed ID: 26898608
[TBL] [Abstract][Full Text] [Related]
39. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
[TBL] [Abstract][Full Text] [Related]
40. Predictive value of peripheral regulatory T cells in non-small cell lung cancer patients undergoing radiotherapy.
Liu C; Wu S; Meng X; Liu G; Chen D; Cong Y; Shen G; Sun B; Wang W; Wang Q; Gao H; Liu X
Oncotarget; 2017 Jun; 8(26):43427-43438. PubMed ID: 28624781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
